Cargando…

Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get

Bimolecular fluorescence complementation (BiFC) was introduced a decade ago as a method to monitor alpha‐synuclein (α‐syn) oligomerization in intact cells. Since then, several α‐syn BiFC cellular assays and animal models have been developed based on the assumption that an increase in the fluorescent...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Bryan, AlOkda, Abdelrahman, Jackson, Matthew P., Riguet, Nathan, Duce, James A., Lashuel, Hilal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246987/
https://www.ncbi.nlm.nih.gov/pubmed/32772367
http://dx.doi.org/10.1111/jnc.15147
_version_ 1783716428026740736
author Frey, Bryan
AlOkda, Abdelrahman
Jackson, Matthew P.
Riguet, Nathan
Duce, James A.
Lashuel, Hilal A.
author_facet Frey, Bryan
AlOkda, Abdelrahman
Jackson, Matthew P.
Riguet, Nathan
Duce, James A.
Lashuel, Hilal A.
author_sort Frey, Bryan
collection PubMed
description Bimolecular fluorescence complementation (BiFC) was introduced a decade ago as a method to monitor alpha‐synuclein (α‐syn) oligomerization in intact cells. Since then, several α‐syn BiFC cellular assays and animal models have been developed based on the assumption that an increase in the fluorescent signal correlates with increased α‐syn oligomerization or aggregation. Despite the increasing use of these assays and models in mechanistic studies, target validation and drug screening, there have been no reports that (1) validate the extent to which the BiFC fluorescent signal correlates with α‐syn oligomerization at the biochemical level; (2) provide a structural characterization of the oligomers and aggregates formed by the BiFC. To address this knowledge gap, we first analysed the expression level and oligomerization properties of the individual constituents of α‐syn‐Venus, one of the most commonly used BiFC systems, in HEK‐293 & SH‐SY5Y cells from three different laboratories using multiple biochemical approaches and techniques. Next, we investigated the biochemical and aggregation properties of α‐syn upon co‐expression of both BiFC fragments. Our results show that (1) the C‐terminal‐Venus fused to α‐syn (α‐syn‐Vc) is present in much lower abundance than its counterpart with N‐terminal‐Venus fused to α‐syn (Vn‐α‐syn); (2) Vn‐α‐syn exhibits a high propensity to form oligomers and higher‐order aggregates; and (3) the expression of either or both fragments does not result in the formation of α‐syn fibrils or cellular inclusions. Furthermore, our results suggest that only a small fraction of Vn‐α‐syn is involved in the formation of the fluorescent BiFC complex and that some of the fluorescent signal may arise from the association or entrapment of α‐syn‐Vc in Vn‐α‐syn aggregates. The fact that the N‐terminal fragment exists predominantly in an aggregated state also indicates that one must exercise caution when using this system to investigate α‐syn oligomerization in cells or in vivo. Altogether, our results suggest that cellular and animal models of oligomerization, aggregation and cell‐to‐cell transmission based on the α‐syn BiFC systems should be thoroughly characterized at the biochemical level to ensure that they reproduce the process of interest and measure what they are intended to measure. [Image: see text]
format Online
Article
Text
id pubmed-8246987
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82469872021-07-02 Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get Frey, Bryan AlOkda, Abdelrahman Jackson, Matthew P. Riguet, Nathan Duce, James A. Lashuel, Hilal A. J Neurochem Original Article Bimolecular fluorescence complementation (BiFC) was introduced a decade ago as a method to monitor alpha‐synuclein (α‐syn) oligomerization in intact cells. Since then, several α‐syn BiFC cellular assays and animal models have been developed based on the assumption that an increase in the fluorescent signal correlates with increased α‐syn oligomerization or aggregation. Despite the increasing use of these assays and models in mechanistic studies, target validation and drug screening, there have been no reports that (1) validate the extent to which the BiFC fluorescent signal correlates with α‐syn oligomerization at the biochemical level; (2) provide a structural characterization of the oligomers and aggregates formed by the BiFC. To address this knowledge gap, we first analysed the expression level and oligomerization properties of the individual constituents of α‐syn‐Venus, one of the most commonly used BiFC systems, in HEK‐293 & SH‐SY5Y cells from three different laboratories using multiple biochemical approaches and techniques. Next, we investigated the biochemical and aggregation properties of α‐syn upon co‐expression of both BiFC fragments. Our results show that (1) the C‐terminal‐Venus fused to α‐syn (α‐syn‐Vc) is present in much lower abundance than its counterpart with N‐terminal‐Venus fused to α‐syn (Vn‐α‐syn); (2) Vn‐α‐syn exhibits a high propensity to form oligomers and higher‐order aggregates; and (3) the expression of either or both fragments does not result in the formation of α‐syn fibrils or cellular inclusions. Furthermore, our results suggest that only a small fraction of Vn‐α‐syn is involved in the formation of the fluorescent BiFC complex and that some of the fluorescent signal may arise from the association or entrapment of α‐syn‐Vc in Vn‐α‐syn aggregates. The fact that the N‐terminal fragment exists predominantly in an aggregated state also indicates that one must exercise caution when using this system to investigate α‐syn oligomerization in cells or in vivo. Altogether, our results suggest that cellular and animal models of oligomerization, aggregation and cell‐to‐cell transmission based on the α‐syn BiFC systems should be thoroughly characterized at the biochemical level to ensure that they reproduce the process of interest and measure what they are intended to measure. [Image: see text] John Wiley and Sons Inc. 2020-10-27 2021-05 /pmc/articles/PMC8246987/ /pubmed/32772367 http://dx.doi.org/10.1111/jnc.15147 Text en © 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
Frey, Bryan
AlOkda, Abdelrahman
Jackson, Matthew P.
Riguet, Nathan
Duce, James A.
Lashuel, Hilal A.
Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title_full Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title_fullStr Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title_full_unstemmed Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title_short Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get
title_sort monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: what you see is not always what you get
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246987/
https://www.ncbi.nlm.nih.gov/pubmed/32772367
http://dx.doi.org/10.1111/jnc.15147
work_keys_str_mv AT freybryan monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget
AT alokdaabdelrahman monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget
AT jacksonmatthewp monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget
AT riguetnathan monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget
AT ducejamesa monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget
AT lashuelhilala monitoringalphasynucleinoligomerizationandaggregationusingbimolecularfluorescencecomplementationassayswhatyouseeisnotalwayswhatyouget